AEterna Zentaris Announces Outcome of Management's Strate...( QUEBEC CITY QC Oct. 2 / AEterna Z...)

QUEBEC CITY, QC, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce today at 11: 00 a.m. Eastern Time, during a live webcast presentation and conference call hosted by President and Chief Executive Officer, David J. Mazzo, Ph.D., the outcome of management's review of the Company's pipeline and business operations along with key elements of the new strategic plan implemented to achieve short-term and long-term success.

David J. Mazzo, President and Chief Executive Officer of AEterna Zentaris stated, "Over the past four months, our Executive Team has been tasked with completing a thorough review of our extensive pipeline and business operations with the goal of creating a strategy optimized for success. As a result of this extensive exercise, we established a harmonized global vision and elucidated our strategic imperatives. Based on a rigorous assessment of the value of our assets, our abilities and resources, the probability of success and return on investment potential of each of our product candidates and our objective to maximize shareholder value, we additionally established a set of priorities and plans to achieve our vision."

During the live webcast, the company will discuss in detail the following fundamentals of their strategic plan.

- AEterna Zentaris is now a multinational company with a clear vision to

eventually become a fully integrated biopharmaceutical company (without

commercial manufacturing). The necessary resources have been identified

and allocated to achieve business success.

- AEterna Zentaris has prioritized its pipeline, developed a partnering

strategy and determined the value of its most immediate assets:

Cetrorelix

Cetrorelix, currently in a Phase 3 program for benign prostatic

hyperplasia (BPH), is clearly the Company's highes
'/>"/>